Voyager Therapeutics, Inc. - Common Stock (NQ:VYGR)

2.450 -0.230 (-8.58%)

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Voyager Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >

Voyager Therapeutics: Return On Capital Employed Insights ↗

June 08, 2021

In Q1, Voyager Therapeutics (NASDAQ:VYGR) posted sales of $6.50 million. Earnings were up 7.84%, but Voyager Therapeutics still reported an overall loss of $25.59 million. In Q4,...

Via Benzinga

The Week Ahead In Biotech (May 23-29): Eton, Lantheus FDA Decisions, Adcom Test For Provention, Chiasma Data Presentation ↗

May 23, 2021

Biotech stocks advanced in the week ended May 21, as risk aversion forced traders to buy into defensives. As earnings news flow tapered, stocks took cues from clinical readouts.

Via Talk Markets

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

May 20, 2021

Gainers PDS Biotechnology (NASDAQ:PDSB) shares increased by 18.99% to $6.83 during Thursday's regular session. PDS Biotechnology's stock is trading at a volume of...

Via Benzinga

Voyager CEO Resigns After Company Turns Back To Discovery-Stage ↗

May 20, 2021

Voyager Therapeutics, Inc (NASDAQ: VYGR) CEO and President Andre Turenne will step down as the beleaguered company announced it would move focus to early,...

Via Benzinga

The Daily Biotech Pulse: Pfizer-BioNTech COVID-19 Order Flow Abounds, Voyager CEO, CMO To Depart, Decision Day For Bristol-Myers Squibb, ASCO Abstracts Move Stocks ↗

May 20, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 19) ESSA Pharma Inc. (NASDAQ:...

Via Benzinga

60 Biggest Movers From Yesterday ↗

May 21, 2021

Gainers Big Rock Partners Acquisition Corp. (NASDAQ: BRPA) shares jumped 88% to settle at $36.08 on Thursday. Urban One, Inc. (NASDAQ: UONE) gained 59.1% to close at $9.56. Urban...

Via Benzinga

Voyager Therapeutics' Vectorized Anti-Tau Antibody Shows Encouraging Preclinical Data In CNS Disorders ↗

May 12, 2021

Voyager Therapeutics Inc (NASDAQ: VYGR) has announced new preclinical data characterizing the durable expression and activity of a vectorized anti-tau...

Via Benzinga

NASDAQ:VYGR Long Term Investor Notice: Investigation over Possible Wrongdoing at Voyager Therapeutics, Inc. ↗

May 05, 2021

San Diego, CA -- (SBWIRE) -- 05/05/2021 -- Certain directors of Voyager Therapeutics, Inc. are under investigation over possible breaches of fiduciary duties.

Via SBWire

Topics Lawsuit

The Daily Biotech Pulse: FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine For Adolescents, Lilly Strikes R&D Collaboration, Vaccine Stocks Novavax, Inovio Sink On Earnings ↗

May 11, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 10) AbbVie Inc. (NYSE: ABBV) -...

Via Benzinga

Stocks That Hit 52-Week Lows On Monday ↗

May 10, 2021

Monday morning saw 78 companies set new 52-week lows. Intriguing Points: The largest company by market cap to set a new 52-week low was Rocket Companies (NYSE:RKT)....

Via Benzinga

Why Voyager Therapeutics, uniQure, Axsome, Reviva Pharma and Crispr Are Moving Today ↗

April 26, 2021

Voyager Therapeutics, Inc. (NASDAQ: VYGR), uniQure N.V. (NASDAQ: QURE), Axsome Therapeutics, Inc. (NASDAQ: AXSM), Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) and CRISPR...

Via Benzinga

The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Moderna Slips On Revenue Miss, Chemocentryx Adcom ↗

May 06, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 5) AbbVie Inc. (NYSE: ABBV)...

Via Benzinga

The Daily Biotech Pulse: Athenex, NeoGenomics And Amryt In M&A Mix, European Nod For Roche's Cancer Immunotherapy, Earnings Deluge Continues ↗

May 05, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 4) AbbVie Inc. (NYSE: ABBV)...

Via Benzinga

58 Biggest Movers From Yesterday ↗

April 27, 2021

Gainers Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) shares jumped 104.2% to close at $8.70 on Monday after the company announced the full details of its Phase 2 trial...

Via Benzinga

12 Health Care Stocks Moving In Monday's Intraday Session ↗

April 26, 2021

Gainers Reviva Pharmaceuticals (NASDAQ:RVPH) shares rose 72.91% to $7.47 during Monday's regular session. Reviva Pharmaceuticals's stock is trading at a volume of...

Via Benzinga

38 Stocks Moving In Monday's Mid-Day Session ↗

April 26, 2021

Gainers Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) surged 46.9% to $6.25 after the company announced the full details of its Phase 2 trial evaluating its lead drug...

Via Benzinga

Voyager Therapeutics' Stock Jumps As FDA Lifts Clinical Hold For Huntington's Disease Gene Therapy ↗

April 26, 2021

Today FDA has removed the clinical hold on one more gene therapy study, this time for Voyager Therapeutics Inc's (NASDAQ: VYGR) investigational new...

Via Benzinga

The Daily Biotech Pulse: Q1 Beat From Johnson & Johnson, KalVista Study Placed On Hold, European Label Expansion For GW Pharma's Epidiolex ↗

April 20, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 15) Alexion Pharmaceuticals,...

Via Benzinga

The Daily Biotech Pulse: Novavax CFO Departs, Zai Lab Inks Cancer Drug Collaboration, FDA Nod For Gilead ↗

April 14, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 13) Bio-Techne Corporation (...

Via Benzinga

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.